America’s Vulnerability in Pharmaceutical Dependence
The reliance on foreign sources for pharmaceutical raw materials poses significant risks to both national security and public health—issues often overlooked.
For years, U.S. manufacturers have turned to cheaper overseas suppliers, especially in China, without ensuring quality and control. This practice has been detrimental, affecting the very fabric of healthcare in America. The previous administration rightly highlighted the need to decouple from the influence of the Chinese Communist Party.
It’s crucial now to focus on revitalizing American manufacturing and addressing the gaps that allow unsafe products to enter the market.
A very telling example is the recent surge in weight loss drugs. While these medications offer potential benefits, they also come with significant risks. The hype surrounding weight loss has allowed questionable supply chains to flourish, particularly involving counterfeit drugs derived from Chinese precursors that should have never made it through U.S. borders. This is not merely about accessibility; it’s a risky pipeline that jeopardizes American health and security.
Data shows alarming trends: from September 2023 to January 2025, more than 230 shipments of raw materials originating from unregistered foreign manufacturers have entered the U.S.—30% of which came from China or Hong Kong. Surprisingly, a staggering 81% of these shipments evade strict regulation.
This isn’t just a matter of temporary stock shortages. Although the FDA listed one precursor as no longer being in shortage back in February 2025, the gray market has thrived due to lax oversight. With demand skyrocketing, new suppliers—mostly from China—have popped up, widely lacking inspection history or quality standards. This situation creates fertile ground for counterfeiters. We’re already witnessing counterfeit Ozempic in circulation, raising alarms and prompting government warnings.
If we truly prioritize safety, we need to stop viewing this as the new norm. It’s time to acknowledge and confront the exploitation led by Beijing. We need to secure our ports of entry. There should be zero tolerance for suppliers not registered with the FDA. If a manufacturer isn’t compliant, their shipments should be held until they are vetted. Poor documentation should lead to rejection of products.
Moreover, we should leverage our diplomatic strength to discourage dependency on risky imports. It’s essential to impose tariffs on bulk raw materials from China to prevent them from undercutting U.S. safety standards. Repeat offenders need to be exposed, and companies wishing to access the U.S. market must adhere to our standards; non-compliance shouldn’t go unpunished. The previous administration’s approach is valid—treating the Chinese Communist Party as a competitive threat rather than a trustworthy supplier.
We must also focus on rebuilding domestic manufacturing capabilities. True strategic resilience means relying on our own resources, and we should explore options like targeted grants and streamlined permitting for new facilities. Plus, let’s bolster “Buy American” preferences in federally funded programs to reduce reliance on foreign suppliers. This initiative is not merely about industrial policy but is crucial for public health and employment stability in the face of future challenges.
U.S. market access must align with law enforcement efforts. If raw materials lack proper registration, those shipments must be stopped. Patients shouldn’t bear the burden of distinguishing between safe and unsafe products; we need a proactive system to intercept faulty products before they land in the market, providing transparency when issues arise.
During my tenure at the Department of Homeland Security, I witnessed how the Chinese government capitalizes on our oversights. Unverified suppliers exploited vulnerabilities. It’s time to change this narrative by enforcing strict penalties, bringing manufacturing back, and applying pressure on China until these unsafe channels are shut down.
Restoring American manufacturing isn’t about longing for the past; it’s about redefining our sovereignty. We know what strategies work: a firm approach against Beijing, stringent border control, and a commitment to strengthening our nation.
